WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 21-Sep-2018 (data as of 18-Sep-2018)
Next overall update spring 2019
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 51'3601 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 47'0471 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 24'451  24'126  23'800  23'475  23'151  19'066  17'041  14'649 
Births 314  312  311  309  307  248  255  228 
Surviving infants 313  311  310  308  306  246  253  225 
Pop. less than 5 years 1'574  1'551  1'545  1'533  1'530  1'283  1'262  1'134 
Pop. less than 15 years 4'649  4'559  4'483  4'421  4'371  3'978  3'764  3'705 
Female 15-49 years 5'765  5'727  5'686  5'635  5'582  4'848  4'508  3'657 

Number of reported cases

(Click for retrospective incidence data for Australia)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  81  99  74  340  158  108  880 
Mumps
ChartChart
  806  800  633  187  216  212 
Pertussis
ChartChart
  12'114  20'037  22'508  11'842  12'319  5'795  862  124 
Polio*
ChartChart
 
Rubella
ChartChart
  11  17  18  17  26  313 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Australia)
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          95  94  93  92  91  90  95  33 
DTP4          94  94  93 
IPV1         
HepB_BD         
HepB3          95  94  93  91  91 
Hib3          95  94  93  91  91  90 
JapEnc         
MCV1          95  94  94  91  86 
MCV2          93  94  93  93  92 
MenA         
PCV1         
PCV2         
PCV3          94  94  93  91  91 
Pol3          95  94  93  92  91  90  72  17 
Rota1         
RotaC          87  85  84  84 
RCV1          95  94  94 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2019

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Australia)
DTP1
ChartChart
  98  98  97  92  92  96  98  58 
DTP3
ChartChart
  95  94  93  92  91  90  95  33 
HepB3
ChartChart
  95  94  93  91  91 
HepB_BD
 
Hib3
ChartChart
  94  94  93  91  91  90 
MCV1
ChartChart
  95  95  95  94  94  91  86 
MCV2
ChartChart
  93  94  93  93  92 
PCV3
ChartChart
  94  94  93  91  91 
Pol3
  95  94  93  92  91  90  72  17 
RCV1
ChartChart
  95  95  95  94  94  91  86 
RotaC
ChartChart
  87  87  85  84  84 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaP 18 months; Yes
DTaPHibHepBIPV 2, 4, 6 months;
DTaPHibHepIPV 2, 4, 6 months; Yes
DTaPIPV 4 years; Yes
HepA_Pediatric 12-24 months (x2 doses); Yes Aboriginal and Torres Strait Islanders
HepB_Adult 10-19 years; >20 years; (x3 doses) Yes Catch-up program provided.
HepB_Pediatric birth; Yes
HibMenC 12 months; Yes
HPV 10-15 years; Yes
Influenza_Adult >=65 years; Yes and adults with chronic illness, pregnant women, health care workers, Haj or other travellers, other risk groups
Influenza_Pediatric >=6 months; Yes and children with chronic illness, Aboriginal and Torres Strait Islander 6-59 months
MMR 12 months; Yes
MMRV 18 months; Yes
Pneumo_conj 2, 4, 6, 12, 12-18 months; 15 years; Yes 12 months medically at risk; 12-18 months Aboriginal and Torres Strait Islander children in high risk areas
Pneumo_ps >= 65 years; Yes 4Y medically at risk; 15+50+ Aboriginal and Torres Strait Islander People
Rotavirus 2, 4, 6 months; Yes from July 2017; 2 dose schedule
Tdap 10-15 years; Yes
Varicella 10-15 years; Yes
Zoster 70, 71-79 years; Yes includes time limited catch up program for 71-79 year olds until 2021

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2013-2018  2013-2018  2013-2018  2013-2018  2013-2018  2009-2013   
Nº of districts with microplans that include activities to raise immunization coverage number        

System performance

Total Nº districts in country number
Nº districts with DTP3 coverage >=80% number    
% of districts with DTP3 coverage >=80% From 0 to 100% 100    100    100  100  100 
Nº districts with measles (MCV1) coverage >=95% number   NA 
% of districts with MCV1 coverage >=95% From 0 to 100%   13  13  13  25 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  No  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%     100  100  100  100  NA 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2018, data for 2016
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.